PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 9, 2026European Journal of Pharmaceutical Sciences0 citationsOpen Access

Long-Term Clinical Outcomes of 0.015% Tacrolimus HPβCD Eye Drops in Ocular Surface Inflammatory Disorders

View Full Paper
MPMaría Puente-IglesiasACAndrea Cuartero-MartínezRTRosario Touriño-Peralba

Key Points

  • To evaluate the long-term efficacy and safety of 0.015% tacrolimus/HPβCD eye drops in treating ocular surface inflammatory disorders.
  • Conducted over 12 months
  • Included diverse ocular inflammatory conditions
  • Analyzed patient-reported outcomes
  • Monitored for corticosteroid dependency
  • Demonstrated sustained clinical stability
  • Reported significant patient-reported benefits
  • Reduced reliance on steroid treatments

Abstract

The 0.015% tacrolimus/HPβCD formulation proves efficacy, and safety over 12 months for the treatment of diverse ocular inflammatory conditions, delivering sustained clinical stability and patient-reported benefits with reduced steroid reliance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Puente-Iglesias et al. (2026) studied this question.

synapsesocial.com/papers/698978dff0ec2af6756e7233https://doi.org/10.1016/j.ejps.2026.107459
Ask AI
Helpful
Bookmark
Share
View Full Paper